Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors

Rebecca A. Haeusler, Kirsten Hartil, Bhavapriya Vaitheesvaran, Isabel Arrieta-Cruz, Colette M. Knight, Joshua R. Cook, Helene L. Kammoun, Mark A. Febbraio, Roger Gutierrez-Juarez, Irwin J. Kurland, Domenico Accili

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Insulin integrates hepatic glucose and lipid metabolism, directing nutrients to storage as glycogen and triglyceride. In type 2 diabetes, levels of the former are low and the latter are exaggerated, posing a pathophysiologic and therapeutic conundrum. A branching model of insulin signalling, with FoxO1 presiding over glucose production and Srebp-1c regulating lipogenesis, provides a potential explanation. Here we illustrate an alternative mechanism that integrates glucose production and lipogenesis under the unifying control of FoxO. Liver-specific ablation of three FoxOs (L-FoxO1,3,4) prevents the induction of glucose-6-phosphatase and the repression of glucokinase during fasting, thus increasing lipogenesis at the expense of glucose production. We document a similar pattern in the early phases of diet-induced insulin resistance, and propose that FoxOs are required to enable the liver to direct nutritionally derived carbons to glucose versus lipid metabolism. Our data underscore the heterogeneity of hepatic insulin resistance during progression from the metabolic syndrome to overt diabetes, and the conceptual challenge of designing therapies that curtail glucose production without promoting hepatic lipid accumulation.

Original languageEnglish (US)
Article number5190
JournalNature Communications
Volume5
DOIs
StatePublished - Oct 13 2014

Fingerprint

Integrated control
Lipogenesis
glucose
Transcription Factors
insulin
Glucose
Liver
Insulin
lipid metabolism
Medical problems
Lipid Metabolism
Insulin Resistance
liver
Glucokinase
fasting
Glucose-6-Phosphatase
glycogens
diets
Nutrition
phosphatases

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Haeusler, R. A., Hartil, K., Vaitheesvaran, B., Arrieta-Cruz, I., Knight, C. M., Cook, J. R., ... Accili, D. (2014). Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nature Communications, 5, [5190]. https://doi.org/10.1038/ncomms6190

Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. / Haeusler, Rebecca A.; Hartil, Kirsten; Vaitheesvaran, Bhavapriya; Arrieta-Cruz, Isabel; Knight, Colette M.; Cook, Joshua R.; Kammoun, Helene L.; Febbraio, Mark A.; Gutierrez-Juarez, Roger; Kurland, Irwin J.; Accili, Domenico.

In: Nature Communications, Vol. 5, 5190, 13.10.2014.

Research output: Contribution to journalArticle

Haeusler, RA, Hartil, K, Vaitheesvaran, B, Arrieta-Cruz, I, Knight, CM, Cook, JR, Kammoun, HL, Febbraio, MA, Gutierrez-Juarez, R, Kurland, IJ & Accili, D 2014, 'Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors', Nature Communications, vol. 5, 5190. https://doi.org/10.1038/ncomms6190
Haeusler, Rebecca A. ; Hartil, Kirsten ; Vaitheesvaran, Bhavapriya ; Arrieta-Cruz, Isabel ; Knight, Colette M. ; Cook, Joshua R. ; Kammoun, Helene L. ; Febbraio, Mark A. ; Gutierrez-Juarez, Roger ; Kurland, Irwin J. ; Accili, Domenico. / Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. In: Nature Communications. 2014 ; Vol. 5.
@article{aaeaa94a30cd424593c64831782db248,
title = "Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors",
abstract = "Insulin integrates hepatic glucose and lipid metabolism, directing nutrients to storage as glycogen and triglyceride. In type 2 diabetes, levels of the former are low and the latter are exaggerated, posing a pathophysiologic and therapeutic conundrum. A branching model of insulin signalling, with FoxO1 presiding over glucose production and Srebp-1c regulating lipogenesis, provides a potential explanation. Here we illustrate an alternative mechanism that integrates glucose production and lipogenesis under the unifying control of FoxO. Liver-specific ablation of three FoxOs (L-FoxO1,3,4) prevents the induction of glucose-6-phosphatase and the repression of glucokinase during fasting, thus increasing lipogenesis at the expense of glucose production. We document a similar pattern in the early phases of diet-induced insulin resistance, and propose that FoxOs are required to enable the liver to direct nutritionally derived carbons to glucose versus lipid metabolism. Our data underscore the heterogeneity of hepatic insulin resistance during progression from the metabolic syndrome to overt diabetes, and the conceptual challenge of designing therapies that curtail glucose production without promoting hepatic lipid accumulation.",
author = "Haeusler, {Rebecca A.} and Kirsten Hartil and Bhavapriya Vaitheesvaran and Isabel Arrieta-Cruz and Knight, {Colette M.} and Cook, {Joshua R.} and Kammoun, {Helene L.} and Febbraio, {Mark A.} and Roger Gutierrez-Juarez and Kurland, {Irwin J.} and Domenico Accili",
year = "2014",
month = "10",
day = "13",
doi = "10.1038/ncomms6190",
language = "English (US)",
volume = "5",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors

AU - Haeusler, Rebecca A.

AU - Hartil, Kirsten

AU - Vaitheesvaran, Bhavapriya

AU - Arrieta-Cruz, Isabel

AU - Knight, Colette M.

AU - Cook, Joshua R.

AU - Kammoun, Helene L.

AU - Febbraio, Mark A.

AU - Gutierrez-Juarez, Roger

AU - Kurland, Irwin J.

AU - Accili, Domenico

PY - 2014/10/13

Y1 - 2014/10/13

N2 - Insulin integrates hepatic glucose and lipid metabolism, directing nutrients to storage as glycogen and triglyceride. In type 2 diabetes, levels of the former are low and the latter are exaggerated, posing a pathophysiologic and therapeutic conundrum. A branching model of insulin signalling, with FoxO1 presiding over glucose production and Srebp-1c regulating lipogenesis, provides a potential explanation. Here we illustrate an alternative mechanism that integrates glucose production and lipogenesis under the unifying control of FoxO. Liver-specific ablation of three FoxOs (L-FoxO1,3,4) prevents the induction of glucose-6-phosphatase and the repression of glucokinase during fasting, thus increasing lipogenesis at the expense of glucose production. We document a similar pattern in the early phases of diet-induced insulin resistance, and propose that FoxOs are required to enable the liver to direct nutritionally derived carbons to glucose versus lipid metabolism. Our data underscore the heterogeneity of hepatic insulin resistance during progression from the metabolic syndrome to overt diabetes, and the conceptual challenge of designing therapies that curtail glucose production without promoting hepatic lipid accumulation.

AB - Insulin integrates hepatic glucose and lipid metabolism, directing nutrients to storage as glycogen and triglyceride. In type 2 diabetes, levels of the former are low and the latter are exaggerated, posing a pathophysiologic and therapeutic conundrum. A branching model of insulin signalling, with FoxO1 presiding over glucose production and Srebp-1c regulating lipogenesis, provides a potential explanation. Here we illustrate an alternative mechanism that integrates glucose production and lipogenesis under the unifying control of FoxO. Liver-specific ablation of three FoxOs (L-FoxO1,3,4) prevents the induction of glucose-6-phosphatase and the repression of glucokinase during fasting, thus increasing lipogenesis at the expense of glucose production. We document a similar pattern in the early phases of diet-induced insulin resistance, and propose that FoxOs are required to enable the liver to direct nutritionally derived carbons to glucose versus lipid metabolism. Our data underscore the heterogeneity of hepatic insulin resistance during progression from the metabolic syndrome to overt diabetes, and the conceptual challenge of designing therapies that curtail glucose production without promoting hepatic lipid accumulation.

UR - http://www.scopus.com/inward/record.url?scp=84922754155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922754155&partnerID=8YFLogxK

U2 - 10.1038/ncomms6190

DO - 10.1038/ncomms6190

M3 - Article

C2 - 25307742

AN - SCOPUS:84922754155

VL - 5

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 5190

ER -